Mar 03, 2022 7:00am EST Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
Feb 25, 2022 2:00am EST Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Jan 26, 2022 7:00am EST Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
Dec 06, 2021 7:00am EST Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
Nov 10, 2021 7:00am EST Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 09, 2021 8:01am EST Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting